Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Ciprofloxacin
93%
Pharmacodynamics
39%
Infection
31%
Antiinfective Agent
30%
Antibiotic Agent
29%
Antacid Agent
29%
Vancomycin
27%
Antibiotics
20%
Tobramycin
19%
Pseudomonas aeruginosa
19%
Staphylococcus Aureus
19%
Enoxacin
18%
Theophylline
18%
Aminoglycoside
18%
Minimum Inhibitory Concentration
18%
Antifungal Agent
18%
Creatinine
17%
Coccidioidomycosis
15%
Injury
15%
Normal Human
14%
Gentamicin
14%
Pharmacokinetic Parameter
14%
Infectious Agent
13%
Piperacillin Plus Tazobactam
12%
Linezolid
12%
Lomefloxacin
12%
Enzymuria
12%
Cefmenoxime
12%
Cefpirome
12%
Bioavailability
12%
Methicillin Resistant Staphylococcus Aureus Infection
12%
Adverse Event
12%
Monotherapy
11%
Cefazolin
11%
Quinolone Derivative
10%
Piperacillin
10%
Ranitidine
10%
Enterobacter Cloacae
10%
Alanine Aminopeptidase
9%
Ticarcillin
9%
Klebsiella pneumoniae
9%
Respiratory Tract Infection
9%
Meticillin
9%
Trovafloxacin
9%
Methicillin-Resistant Staphylococcus Aureus
8%
Placebo
8%
Ethionamide
8%
Volume of Distribution
8%
High Performance Liquid Chromatography
8%
Keyphrases
Pharmacokinetics
32%
Antacids
25%
Ciprofloxacin
20%
Enoxacin
18%
Lomefloxacin
12%
Orange Juice
12%
Fasting Condition
12%
Sucralfate
12%
Community-acquired Pneumonia
12%
Ranitidine
10%
Area under the Concentration-time Curve
10%
Pseudomonas Aeruginosa (P. aeruginosa)
9%
Confidence Interval
8%
Aminoglycosides
8%
Cmax
7%
Population Pharmacokinetics
7%
Ethambutol
7%
Relative Bioavailability
7%
Fluoroquinolones
7%
Doxycycline
7%
Ethionamide
7%
High Dose
6%
Trough Concentration
6%
Multiple-dose Activated Charcoal
6%
Hospital-acquired Conditions Reduction Program
6%
Pharmacokinetic Simulation
6%
Turbidimetric Assay
6%
Intravenous Dose
6%
Itraconazole
6%
Cystatin C (Cys C)
6%
Risk Ratio
6%
Candiduria
6%
Gatifloxacin
6%
Perioperative Antibiotics
6%
Microbial Keratitis
6%
Pediatric Case
6%
In Vitro Selection
6%
Trauma Patients
6%
Vaginal Mesh
6%
Piperacillin-tazobactam
6%
Pharmacokinetic Effects
6%
Ertapenem
6%
Adverse Outcomes
6%
Atypical Bacteria
6%
Histoplasmosis
6%
Surgical Site Infection Prevention
6%
Enrollment Criteria
6%
Seriously Ill Patients
6%
Meta-analysis
6%
Adverse Drug Events
6%